PM Modi visits Covid-19 Vaccine manufacturing facility in Ahmedabad & Hyderabad

Prime Minister Narendra Modi reached Ahmedabad on a 3 city visit today morning to personally review the vaccine development & manufacturing process. Mr. Modi visited the Zydus Cadila Pharmaceutical’s vaccine development facility and held discussions with the scientists and vaccine developers.

AIR correspondent reports that Zydus Cadila Pharmaceutical’s vaccine development facility at Zydus Biotech Park is working on ZyCoV-D, a Covid19 vaccine candidate is located in Changodar area of Ahmedabad

Prime Minister Narendra Modi was welcomed by Pankaj Patel – the Chairman and Sharvil Patel- Managing Director of  Zydus Cadila Pharmaceuticals on his arrival at the  Zydus Biotech Park in Ahmedabad. During the half an hour meeting, Prime Minister Modi discussed the process of vaccine development, its trials and distribution of the final product. Zydus Cadila Pharmaceutical’s vaccine development facility at Zydus Biotech Park is working on ZyKoV-D, a Covid19 vaccine candidate. Zydus Cadila is expected to submit the results of its Phase 2 trials next week, which will ascertain the safety, dose and efficacy of the potential vaccine. It will also apply for Phase three clinical trials of its experimental COVID-19 vaccine in December. The company is expected to roll out the final product by March next year after the success of all trials. 

After his visit to the Zydus Biotech Park in Ahmedabad, in a tweet, Mr Modi said that he had complimented the team behind this effort for their work. He said, the Government of India is actively working with them to support them in this journey.

From Ahmedabad the Prime Minister then flew to Hyderabad and arrived at the Air Force Station at Hakimpet. He was welcomed by State Chief Secretory Somesh Kumar, State DGP Mahender Reddy Medchal Malkajgiri Collector Swetha Mohanthy among other senior officials.  Our Hyderabad Correspondent reports that the Prime Minister reached Bharat Biotech International Limited in the Genome Valley located near Shamirpet on the outskirts of Hyderabad. The Prime Minister met with Scientists and discussed with them about the roadmap of the vaccine production and supply.
AIR correspondent reports Prime Minister Narendra Modi has reached the Bharat Biotech International Limited (BBIL) located at the Genome Valley on the outskirts of Hyderabad and reviewing the development and manufacturing process relating to COVID-19 Vaccine.
 He has taken up rounds to the vaccine manufacturing installations where the processes are underway for COVID-19 Vaccine, called Covaxin and visiting the Bio-Safety Level 3 laboratory. He is interacting with the senior scientists and other concerned at the BBIL and being briefed about the progress made so far relating to manufacturing of the Covaxin.
It may be recalled that the BBIL has taken up the manufacturing of the vaccine in collaboration with the Indian Council of Medical Research (ICMR). The SARS-CoV-2 strain for the indigenous COVID-19 vaccine candidate was isolated in the Pune Based ICMR- National Institute of Virology and transferred to BBIL. Currently the phase-III clinical trials of the Covaxin are underway by involving over 25 thousand volunteers in 22 states across the country.
The vaccine has already been tested on around thousand volunteers during the I and II phases of the trails. The prime minister’s visit highlights the importance that the Government attached to make the country self-reliant in its fight against the COVID-19 pandemic. He will be leaving for Pune later today afternoon.


The Dispatch is present across a number of social media platforms. Subscribe to our YouTube channel for exciting videos; join us on Facebook, Intagram and Twitter for quick updates and discussions. We are also available on the Telegram. Follow us on Pinterest for thousands of pictures and graphics. We care to respond to text messages on WhatsApp at 8082480136 [No calls accepted]. To contribute an article or pitch a story idea, write to us at [email protected] |Click to know more about The Dispatch, our standards and policies   

About the author

The Dispatch Staff

Add Comment

Click here to post a comment